Atharva R. Bhide
Birla Institute of Technology and Science
5 Papers
9 Citations
Atharva R. Bhide is an academic researcher from Birla Institute of Technology and Science. The author has contributed to research in topics: Nanorod & Chemistry. The author has an hindex of 1, co-authored 2 publications.
Chat about Author
Papers
Long-acting Parenteral Drug Delivery Systems for the Treatment of Chronic Diseases.
TL;DR: The use of long-acting parenteral formulations for the treatment of chronic infections such as HIV/AIDS and tuberculosis is a recent development in the field as discussed by the authors , which has the potential to improve the treatment for chronic conditions.
35
Fabrication and evaluation of artemether loaded polymeric nanorods obtained by mechanical stretching of nanospheres
Atharva R. Bhide,Anil B. Jindal +1 more
TL;DR: Artemether-loaded poly (lactic-co-glycolic acid) (PLGA) nanorods were successfully prepared by the film stretching method for intravenous delivery of antimalarial drugs.
9
A sensitive RP-HPLC method for estimation of artemether from polymeric nanoparticles after pre-column acid treatment using UV-visible detector
TL;DR: Artemether; a sesquiterpene lactone is widely used for the treatment of malaria as artemisinin-based combination therapy (ACT) as discussed by the authors.
6
Evaluation of Pharmacokinetics, Biodistribution, and Antimalarial Efficacy of Artemether-Loaded Polymeric Nanorods.
Atharva R. Bhide,Mansi Suri,Sapna Katnoria,Sukhbir Kaur,Yugandhara B Jirwankar,Vikas Dighe,Anil B. Jindal +6 more
TL;DR: In this article , the authors evaluated the antimalarial efficacy of artemether-loaded polymeric nanorods for the treatment of severe malaria by the intramuscular route.
5
Nanocarrier based active targeting strategies against erythrocytic stage of malaria.
TL;DR: The complex interaction between erythrocytic receptors and parasites is understood and platforms technologies with established pre-clinical safety and efficacy should be translated into clinical evaluation and formulation scale-up and future development should be directed towards nanovaccines as proactive tools against malaria infection.